Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT00267592
First received: December 19, 2005
Last updated: March 19, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 16, 2011